- ICH GCP
- Registr klinických hodnocení EU
Poslední zkoušky
EudraCT Number: 2022-003588-55 | Sponsor Protocol Number: 20221102 | Start Date: 2024-10-14 | ||||||
Sponsor Name: Isala | ||||||||
Full Title: Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study | ||||||||
Medical condition: Oncology | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Trial now transitioned) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004755-17 | Sponsor Protocol Number: MYST-FACT | Start Date: 2024-10-01 | |||||||||||
Sponsor Name: FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: PHASE I/II CLINICAL TRIAL OF ALLOGENEIC BONE MARROW DERIVED MESENCHYMAL STROMAL CELL THERAPY FOR THE PREVENTION AND TREATMENT OF PULMONARY FIBROSIS SECONDARY TO POST-INFECTIVE ARDS OR ALLOIMMUNE RE... | |||||||||||||
Medical condition: PULMONARY FIBROSIS SECONDARY TO ARDS OR ALLOIMMUNE REACTION AFTER TRANSPLANTATION | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002770-82 | Sponsor Protocol Number: RR202200317 | Start Date: 2024-09-09 | |||||||||||
Sponsor Name: Universitair Medisch Centrum Groningen | |||||||||||||
Full Title: The use of FAPI-PET/CT scan and FDG-PET?CT scan in acute phase Peyronie's disease for detection of active fibroblasts and inflammation in the penis - a pilot study | |||||||||||||
Medical condition: Peyronie's disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002373-22 | Sponsor Protocol Number: hNSCALSII | Start Date: 2024-05-31 | ||||||
Sponsor Name: FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS | ||||||||
Full Title: Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical Trial | ||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: IT (Trial now transitioned) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001152-39 | Sponsor Protocol Number: SSG XX | Start Date: 2024-05-21 | ||||||
Sponsor Name: Scandinavian Sarcoma Group | ||||||||
Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall | ||||||||
Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NO (Completed) SE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004231-25 | Sponsor Protocol Number: MS201923_0050 | Start Date: 2024-05-21 | |||||||||||
Sponsor Name: Merck Healthcare KGaA | |||||||||||||
Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer | |||||||||||||
Medical condition: Relapsed platinum resistant small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004633-21 | Sponsor Protocol Number: APHP191047 | Start Date: 2024-04-29 | ||||||
Sponsor Name: Assistance Publique -Hopitaux de Paris | ||||||||
Full Title: | ||||||||
Medical condition: | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: FR (Trial now transitioned) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003745-11 | Sponsor Protocol Number: 1346-0014 | Start Date: 2024-03-02 | |||||||||||
Sponsor Name: Boehringer Ingelheim | |||||||||||||
Full Title: An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) FI (Trial now transitioned) HR (Trial now transitioned) AT (Trial now transitioned) BG (Ongoing) PT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000005-12 | Sponsor Protocol Number: CRCFC-TEICO.SA.2022 | Start Date: 2024-02-21 | ||||||||||||||||
Sponsor Name: AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | ||||||||||||||||||
Full Title: An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS | ||||||||||||||||||
Medical condition: cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003922-27 | Sponsor Protocol Number: PAM-UMCG-002 | Start Date: 2024-02-08 | ||||||
Sponsor Name: University Medical Center Groningen (UMCG) | ||||||||
Full Title: Neo-adjuvant Pembrolizumab as alternative to radio(chemo)therapy in MMRd uterine cancer | ||||||||
Medical condition: Primary uterine cancer characterized with dMMR | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |